Follicular dendritic cell sarcoma treated with a variety of chemotherapy. Issue 4 (13th October 2016)

• Record Type: Journal Article
• Authors: Sasaki, Masaoki; Izumi, Hiroaki; Yokoyama, Takaaki; Kojima, Motohiro; Hosono, Ako
• Is Part Of: Hematological oncology. Volume 35:Issue 4(2017:Dec.)
• Page Start: 905
• Page End: 908
• Publication Date: 2016-10-13
• Subjects: bendamustine -- chemotherapy -- follicular dendritic cell sarcoma; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2364
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed. The present case had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy regimens, which follow therapeutic strategies for malignant lymphoma and soft tissue sarcoma. As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients.